title: Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma.
abstract: The aim of this study was to evaluate the effect of Cabergoline on insulin sensitivity, inflammatory markers, and carotid intima media thickness in prolactinoma patients. Twenty-one female, newly diagnosed patients with prolactinoma were included in the study. None of the patients were treated previously. Cabergoline was given as treatment, starting with 0.5 mg/day and tapered necessarily. Blood samples were taken for prolactin, highly sensitive C-reactive protein, homocysteine, total cholesterol, low density lipoprotein (LDL) cholesterol, fasting glucose, insulin, and HOMA (homeostasis model assessment of insulin resistance) score was calculated, prior to and 6 months after starting treatment. The body mass index (BMI) was measured and carotid intima media thickness (CIMT) was evaluated for each patient prior to and 6 months after the treatment. The prolactin levels and LDL decreased significantly after cabergoline treatment. Insulin sensitivity improved independently from the decrease in prolactin levels and BMI. The significant decrease in homocysteine and hs-CRP was not related with the decrease in prolactin levels. The significant decrease in CIMT was independent from the decrease in prolactin levels, HOMA score, and BMI. Our data suggest that cabergoline treatment causes an improvement in insulin sensitivity and inflammatory markers and causes a decrease in CIMT independent from the decrease in prolactin, LDL cholesterol, and BMI. We conclude that short term cabergoline treatment can improve endothelial function independently from the changes in metabolic disturbances and inflammatory markers.
authors.affiliation: Department of Endocrinology and Metabolism, School of Medicine, Near East University, Nicosia, Cyprus. inanclis@yahoo.com
authors.forename: Serap Soytac
authors.initials: SS
authors.lastname: Inancli
authors.forename: Alper
authors.initials: A
authors.lastname: Usluogullari
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Ustu
authors.forename: Sedat
authors.initials: S
authors.lastname: Caner
authors.forename: Abbas Ali
authors.initials: AA
authors.lastname: Tam
authors.forename: Reyhan
authors.initials: R
authors.lastname: Ersoy
authors.forename: Bekir
authors.initials: B
authors.lastname: Cakir
mesh_terms: D000293:Adolescent; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology* / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood*; D000077465:Cabergoline; D059168:Carotid Intima-Media Thickness; D004873:Ergolines / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007249:Inflammation / Q000097:blood*; D007333:Insulin Resistance; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D015175:Prolactinoma / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D055815:Young Adult
chemical_list: D018931:Antineoplastic Agents, Hormonal; D015415:Biomarkers; D004873:Ergolines; D000077465:Cabergoline